A Potential In Vitro and In Vivo anti-HIV Drug Screening System for Chinese Herbal Medicines

被引:13
|
作者
Feng, Long [1 ,2 ]
Wang, Li [3 ]
Ma, Yun-yun [4 ]
Li, Min [1 ]
Zhao, Guo-Qiang [1 ]
机构
[1] Zhengzhou Univ, Coll Basic Med Sci, Dept Microbiol & Immunol, Zhengzhou 450001, Henan, Peoples R China
[2] Henan Univ TCM, Dept Pathogen Organism Biol, Zhengzhou 450008, Henan, Peoples R China
[3] Zhengzhou Univ, Coll Basic Med Sci, Dept Pathogen Biol, Zhengzhou 450001, Henan, Peoples R China
[4] Henan Med Coll Staff & Workers, Zhengzhou 451191, Henan, Peoples R China
关键词
Spica Prunellae; Herba Andrographitis; CXCR4; promoter; CCR5; Chinese herbal medicines; traditional Chinese medicine; anti-HIV drugs; IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION; INHIBITION; MUTATIONS; PROTEASE; ALLELE;
D O I
10.1002/ptr.3658
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chinese herbal medicines are often applied as an alternative therapy for viral diseases. However, the development of anti-HIV herbal drugs has proceeded slowly, partly because of the lack of a high-throughput system for screening these drugs. The present study evaluated 16 herbal medicines for anti-HIV activities in vitro and in vivo. Herbal medicines were first screened for the ability to regulate C-X-C receptor 4 (CXCR4) and C-C receptor 5 (CCR5) promoter activities. A single-round pseudotyped HIV-luciferase reporter virus system (HIV-Luc) was used to identify potential anti-HIV mechanisms. CD4+ T cells from healthy volunteers were examined for changes in CXCR4 and CCR5 levels. HIV-1 replication was evaluated by ELISA. Spica Prunellae and Herba Andrographitis were found to down-regulate the activities of both the CXCR4 and CCR5 promoters. Also, Spica Prunellae and Herba Andrographitis (>1000?mu m) inhibited HIV-1 in a dose-dependent manner. CXCR4 and CCR5 levels were reduced in CD4+ T cells from healthy volunteers (p?<?0.05). Spica Prunellae and Herba Andrographitis (EC50: 3.18 and 5.49?mu g/mL, respectively) could suppress cell fusion and decrease p24 antigen. In conclusion, the data demonstrated that Spica Prunellae and Herba Andrographitis possessed anti-HIV-1 capabilities, perhaps through the inhibition of the CXCR4 and CCR5 promoters and HIV-1 replication. Copyright (c) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:899 / 907
页数:9
相关论文
共 50 条
  • [41] In vitro screening for the carcinogenicity of nine oriental herbal medicines
    Kam, H.
    Kang, H. J.
    Kim, S. H.
    Lee, M. O.
    TOXICOLOGY LETTERS, 2010, 196 : S177 - S177
  • [42] In vitro screening for the carcinogenicity of eight oriental herbal medicines
    Kam, H.
    Kang, H. J.
    Kim, S. H.
    Lee, M. O.
    TOXICOLOGY LETTERS, 2010, 196 : S181 - S181
  • [43] Anti-cancer potential of traditional Chinese herbal medicines and microbial fermentation products
    Chui, CH
    Gambari, R
    Lau, FY
    Teo, ITN
    Ho, KP
    Cheng, GYM
    Ke, B
    Higa, T
    Kok, HL
    Chan, ASC
    Tang, JCO
    MINERVA BIOTECNOLOGICA, 2005, 17 (03) : 183 - 191
  • [44] In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs
    Uckun, FM
    Qazi, S
    Venkatchalam, TK
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2005, 55 (04): : 223 - 231
  • [45] In Silico Investigation of a HIV-1 Vpr Inhibitor Binding Site: Potential for Virtual Screening and anti-HIV Drug Design
    Choi, Sy Bing
    Choong, Yee Siew
    Saito, Akiko
    Wahab, Habibah A.
    Najimudin, Nazalan
    Watanabe, Nobumoto
    Osada, Hiroyuki
    Ong, Eugene Boon Beng
    MOLECULAR INFORMATICS, 2014, 33 (11-12) : 742 - 748
  • [46] Effects of Chinese herbal medicines on intestinal drug absorption
    Nishimura, N
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2005, 125 (04): : 363 - 369
  • [47] Synthesis of a nucleoside bioconjugate system as a potential anti-HIV agent
    Van Calenbergh, S
    Nair, V
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1999, 18 (4-5): : 737 - 738
  • [48] Anti-HIV drug splits opinion
    Wilson, Clare
    NEW SCIENTIST, 2015, 228 (3050) : 14 - 14
  • [49] Anti-HIV drug design and therapy
    Ross, TM
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (32) : 4003 - 4003
  • [50] ANTI-HIV DRUG AVAILABLE IN TRIALS
    RANDALL, PS
    POSTGRADUATE MEDICINE, 1990, 88 (07) : 23 - 23